



## Technology Advisory Committee C Interests Register Risdiplam for treating spinal muscular atrophy in children and adults [ID1631] Publication Date: 16 December 2021

Name **Role with NICE** Type of interest **Description of interest** Comments Interest Interest Interest declared arose ceased Professor Committee Member Non-financial **Professor Matthew** N/A 21.04.2021 N/A It was agreed that Matthew professional Stevenson declared a his declaration non-financial professional would not prevent Stevenson interest Professor interest as he is employed by ScHARR which was Stevenson from the ERG for risdiplam and participating in the he peer reviewed the draft discussion of the ERG report. appraisal, however he would not be a voting committee member if a vote was required to determine the outcome of the appraisal. Mr Michael Committee Member Financial N/A It was agreed that Mr Chambers has recently 26.04.2021 N/A Chambers been involved in cohis declaration ordinating a training would not prevent programme in real world Mr Chambers from evidence for Roche participating in the **Pharmaceuticals** discussion of the (manufacturer of appraisal. risdiplam), but this has not


involved any specific



|                        |                  |                               | consideration of Roche products.  |     |            |     |   |
|------------------------|------------------|-------------------------------|---|-----|------------|-----|---|
| Dr Richard<br>Nicholas | Committee Member | Financial                     | Dr Nicholas has attended paid advisory boards for Roche and Novartis in an unrelated area.  | N/A | 26.04.2021 | N/A | It was agreed that this declaration would not prevent Dr Nicholas from participating in the discussion of the appraisal.  |
| Dr Prithwiraj Das      | Committee Member | Non-financial<br>professional | Dr Das is employed by<br>AstraZeneca UK as the<br>Head of Market Access<br>for Respiratory and<br>Immunology therapies<br>and Vaccines.   | N/A | 10.05.2021 | N/A | It was agreed that this declaration would not prevent Dr Das from participating in the discussion of the appraisal.       |
| Dr Robert Forsyth      | Committee Member | Non-financial<br>professional | Dr Forsyth is a paediatric neurologist and, whilst not directly involved in the care of neuromuscular diseases (such as SMA) in children, he has made the diagnosis of SMA in children. He also knows many if not most of the paediatric neurologists caring for SMA in the UK professionally. He was also asked to act as a non-voting | N/A | 11.05.2021 | N/A | It was agreed that these declarations would not prevent Dr Forsyth from participating in the discussion of the appraisal. |



|                          |                 |                          | member/advisor for the nusinersen MAOC.  |     |  |     |   |
|--------------------------|-----------------|--------------------------|--|-----|--|-----|---|
| Dr Anne-Marie<br>Childs  | Clinical expert | Financial & professional | Dr Childs has received professional fees to contribute to advisory boards for Roche, Biogen and Avexis in relation to drug development in SMA.  Dr Childs is PI for the observational SMA REACH and iSMAC in Leeds Children's Hospital and is also a medical trustee for SMA UK and a member of the NHSE clinical panel supporting the MAA for nusinersen. | N/A | 14.10.2020<br>11.05.2021               | N/A | It was agreed that these declarations would not prevent Dr Childs from providing expert advice to the committee.      |
| Dr Channa<br>Hewamadduma | Clinical expert | Financial & professional | Dr Hewamadduma has received payment from Biogen for delivering a talk on nusinersen treatment in adult patients. He is developing PROMS for adult SMA patients in collaboration with Biogen.  Dr Hewamadduma chaired a webinar organised by Biogen on 24 June 2021 on sharing  | N/A | 16.10.2020<br>11.05.2021<br>13.07.2021 | N/A | It was agreed that these declarations would not prevent Dr Hewamadduma from providing expert advice to the committee. |



| best practice in setting up adult nusinersen services across UK.   |
|--|
| Dr Hewamadduma has received payment for being on an advisory board of clinical experts for critical analysis of the Roche clinical trial dataset and has taken part in two 'one off' advisory roles to Roche in critical appraisal of evidence for risdiplam |
| Roche organised for Dr Hewamadduma to attend the SMA Europe meeting in February 2020 and also provided him with a travel grant which enabled him to attend the SMA conference.   |